Anacor Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Anacor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013092
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The company’s marketed products include a topical solution which is an oxaborole antifungal that is used for the topical treatment of onychomycosis of the toenails. Its lead pipeline candidates encompass a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis; and an antibiotic for the potential treatment of infections caused from gram-negative bacteria. Anacor’s boron chemistry platform is used to treat diseases in animals caused due to bacteria, fungi and parasites. It out-licensed three investigational compounds: indication targeted at the treatment of an animal health to Eli Lilly and Company; indication for the treatment of human African trypanosomiasis to Drugs for Neglected Diseases; and indication targeted at the treatment of tuberculosis to GlaxoSmithKline LLC. Anacor is headquartered in Palo Alto, California, the US.

Anacor Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Equity Offering 18
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Debt Offering 23
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Acquisition 29
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc – Key Competitors 31
Anacor Pharmaceuticals Inc – Key Employees 32
Anacor Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
May 10, 2016: Anacor Pharmaceuticals Reports First Quarter 2016 Financial Results 34
Feb 29, 2016: Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc, Key Competitors 31
Anacor Pharmaceuticals Inc, Key Employees 32

★海外企業調査レポート[Anacor Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chiyoda Corporation:企業の戦略・SWOT・財務分析
    Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report Summary Chiyoda Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Japan Pulp and Paper Co Ltd:戦略・SWOT・企業財務分析
    Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Promaxo Inc:医療機器:M&Aディール及び事業提携情報
    Summary Promaxo Inc (Promaxo) is a medical device company with focus on the development of portable MRI and other technology. The company develops and commercializes office-based, portable magnetic resonance imaging (MRI) devices that possess cellular spatial resolution, besides targeted biopsy and …
  • McLane Company Inc:戦略・SWOT・企業財務分析
    McLane Company Inc - Strategy, SWOT and Corporate Finance Report Summary McLane Company Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Printpack Inc:企業の戦略的SWOT分析
    Printpack Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Arqvia Group Ltd:企業の戦略・SWOT・財務分析
    Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nine Entertainment Co. Holdings Ltd:企業の戦略・SWOT・財務情報
    Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Real Goods Solar Inc (RGSE):電力:M&Aディール及び事業提携情報
    Summary Real Goods Solar Inc (Real Goods Solar), doing business as RGS Energy, a subsidiary of Gaia Inc is a renewable energy company that offers solar energy products and solutions. The company's services include solar PV system designing, installation, consultation, maintenance, rebate acquisition …
  • IRB Infrastructure Developers Ltd:企業の戦略・SWOT・財務情報
    IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report Summary IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Exterran Corp (EXTN):石油・ガス:M&Aディール及び事業提携情報
    Summary Exterran Corp (Exterran) is an energy service company that provides compression, production and processing products; and offers services that support the production and transportation of oil and natural gas. The company owns and operates natural gas compression equipment; and crude oil and n …
  • Royal Mail plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Juniper Networks, Inc.:企業の戦略・SWOT・財務情報
    Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Taiflex Scientific Co., Ltd. (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co., Ltd. (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Omega Diagnostics Group Plc (ODX):企業の製品パイプライン分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company offers products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests fo …
  • PostNL N.V.:企業の戦略・SWOT・財務情報
    PostNL N.V. - Strategy, SWOT and Corporate Finance Report Summary PostNL N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Qatar Electricity & Water Co QPSC (QEWS):企業の財務・戦略的SWOT分析
    Qatar Electricity & Water Co QPSC (QEWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Qinetiq Group Plc:企業の戦略・SWOT・財務分析
    Qinetiq Group Plc - Strategy, SWOT and Corporate Finance Report Summary Qinetiq Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Optiscan Imaging Limited (OIL):製品パイプライン分析
    Summary Optiscan Imaging Limited (Optiscan) is a technology and product development company. It focuses on the development and application of microscopic imaging technologies for medical procedures. The company’s key product is ViewnVivo, a miniaturized fluorescence endo-microscope platform that bri …
  • Central Rand Gold Ltd:企業の戦略・SWOT・財務情報
    Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bonvests Holdings Limited:企業の戦略・SWOT・財務情報
    Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonvests Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆